Laurent Pharmaceuticals
Laurent Pharmaceuticals is a Montreal-based biopharmaceutical company dedicated to developing treatments for complex degenerative conditions with high unmet needs. They leverage over 10 years of clinical development experience with their lead compound LAU-7b, focusing on respiratory diseases such as cystic fibrosis and COVID-19. The company's mission is to explore innovative therapeutic approaches to improve patient outcomes in serious health conditions.
Industries
Nr. of Employees
small (1-50)
Laurent Pharmaceuticals
Products
LAU-7b
Oral small-molecule candidate developed as a once-daily therapy with host-directed antiviral activity and inflammation-resolving properties; investigated for cystic fibrosis, hospitalized COVID-19 and Long COVID in Phase 2/2–3 studies.
LAU-7b
Oral small-molecule candidate developed as a once-daily therapy with host-directed antiviral activity and inflammation-resolving properties; investigated for cystic fibrosis, hospitalized COVID-19 and Long COVID in Phase 2/2–3 studies.
Services
Sponsor-led clinical development and trial management
Design and sponsor multi-center Phase 2/Phase 2–3 clinical trials for respiratory indications, including protocol development, endpoint selection, operational execution, safety monitoring and data dissemination.
Sponsor-led clinical development and trial management
Design and sponsor multi-center Phase 2/Phase 2–3 clinical trials for respiratory indications, including protocol development, endpoint selection, operational execution, safety monitoring and data dissemination.
Expertise Areas
- Clinical trial management (Phase 2/3)
- Respiratory disease therapeutics development
- Host-directed antiviral strategies
- Anti-inflammatory drug development
Key Technologies
- Oral small-molecule therapeutic development
- Host-directed antiviral approaches
- Pro-resolving anti-inflammatory mechanisms
- Preclinical animal models of respiratory and neurological inflammation